Almagul Kurmanova | Immunology | Innovative Research Award

Published on by Citation Awards

Innovative Research Award

Almagul Kurmanova
Affiliation Farabi University
Country Kazakhstan
Scopus ID 56896046600
Documents 52
Citations 1,928
h-index 10
Subject Area Immunology
Event International Research Excellence And Citation Awards
ORCID 0000-0002-1859-3903

Almagul Kurmanova
Farabi University

Almagul Kurmanova is a researcher associated with Farabi University in Kazakhstan whose scholarly contributions have attracted significant academic attention within the field of immunology. Her publication portfolio, citation record, and sustained research activity reflect engagement with contemporary biomedical and immunological investigations. The combination of documented scholarly output, international visibility, and measurable citation impact provides a foundation for consideration within academic recognition programs and research excellence initiatives.[1][2]

Abstract

This article presents a scholarly overview of Almagul Kurmanova and her academic profile in immunology. Drawing upon publicly available author metrics, publication records, and researcher identifiers, the article summarizes research productivity, scientific influence, and academic visibility. The assessment is intended to provide a structured academic perspective relevant to the Innovative Research Award and the International Research Excellence And Citation Awards program.[1][3]

Keywords

  • Immunology
  • Biomedical Research
  • Citation Impact
  • Research Excellence
  • Scientific Publications
  • Academic Recognition
  • Scholarly Metrics

Introduction

Scientific awards frequently evaluate a combination of research productivity, citation influence, publication quality, and contributions to disciplinary advancement. Within the biomedical sciences, immunology remains a rapidly evolving field that supports developments in disease prevention, diagnosis, treatment, and public health. Researchers whose work demonstrates sustained scholarly engagement and measurable impact often become candidates for international recognition programs.[4]

Research Profile

The available bibliometric profile indicates that Almagul Kurmanova has produced 52 indexed scholarly documents and accumulated approximately 1,928 citations. These metrics demonstrate sustained research engagement and evidence of influence within relevant scientific communities. Her Scopus author profile and ORCID identifier contribute to transparency, discoverability, and research attribution across international scholarly databases.[1][2]

Research Contributions

Kurmanova’s scholarly activities have contributed to the advancement of biomedical and immunological knowledge through peer-reviewed research publications. The visibility of her work, reflected in citation accumulation and scholarly referencing, indicates that her findings have been utilized by researchers across related disciplines. Such contributions support evidence-based scientific dialogue and strengthen the cumulative development of immunological research.[1][5]

Publications

The research portfolio includes publications indexed in major academic databases. These works contribute to the evidence base of immunological and biomedical investigations and provide measurable indicators of academic productivity.[1]

  • Indexed scholarly documents: 52.
  • Research outputs catalogued through Scopus and Google Scholar.
  • Persistent researcher identification through ORCID.
  • International discoverability through standardized author profiles.

Research Impact

Research impact is commonly evaluated through citation counts, publication quality, scholarly influence, and the dissemination of knowledge. With nearly two thousand citations and a measurable h-index, Kurmanova’s body of work demonstrates visibility within the academic ecosystem. Citation activity suggests that her publications have contributed to ongoing scientific discussions and have served as reference points for subsequent investigations.[1][2]

Award Suitability

Based on publicly available scholarly indicators, Almagul Kurmanova demonstrates several characteristics commonly associated with candidates for international research recognition. These include an established publication record, documented citation influence, institutional affiliation with a recognized university, and participation in globally indexed scholarly communication systems.[1][2]

Conclusion

Almagul Kurmanova’s academic profile reflects a combination of research productivity, citation influence, and scholarly visibility within immunology. Her publication record and documented impact metrics provide evidence of meaningful engagement with the scientific community. These attributes support consideration for recognition through the Innovative Research Award and related international academic distinction programs.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Almagul Kurmanova, Author ID 56896046600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56896046600
  2. ORCID. (n.d.). Researcher Profile: Almagul Kurmanova.
    https://orcid.org/0000-0002-1859-3903
  3. Google Scholar. (n.d.). Scholar Citations Profile: Almagul Kurmanova.
    https://scholar.google.com/citations?user=nXt-z4AAAAAJ&hl=en&oi=sra
  4. International Research Excellence And Citation Awards. (n.d.). Award evaluation framework and academic recognition criteria.
    https://citationawards.com/
  5. The Lancet. (2020). Clinical and immunological studies in biomedical science.
    DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

Jacob Gopas | Immunology and Microbiology | Best Researcher Award

Published on by Citation Awards

Jacob Gopas | Immunology and Microbiology | Best Researcher Award

Prof Jacob Gopas, Ben-Gurion University of the Negev, Israel

Professor Jacob Gopas is a distinguished Israeli-Mexican biomedical scientist renowned for his contributions to cancer immunology and biomedical ethics. Born on February 4, 1954, in Mexico City, he pursued an academic career that spans microbiology, immunology, and cancer research. He earned his Ph.D. from the Albert Einstein College of Medicine in New York and has held various prestigious academic positions at Ben-Gurion University of the Negev. He served as Head of the Oncology Laboratory at Soroka Medical Center for over 35 years. In addition to his research, Professor Gopas has played pivotal roles in national and institutional ethics committees, significantly shaping animal experimentation policy in Israel. As a professor in the Faculty of Health Sciences, he has trained generations of students in microbiology and cancer biology. His interdisciplinary research has addressed Hodgkin’s lymphoma, novel anti-cancer compounds, and the impact of sleep apnea on cardiac cells, supported by prestigious international and national grants.

Publication Profile

google scholar

Education

Jacob Gopas began his academic journey with a B.Sc. in Microbiology (1971–1975) at Bar-Ilan University, Ramat Gan, Israel. He continued at Bar-Ilan for his M.Sc. (1975–1977) under Prof. Arye Rozenszajn, researching the impact of hemopoietic factors on lymphocyte colony formation. He then earned a Ph.D. in Cell Biology (1977–1982) from the Albert Einstein College of Medicine, New York, under Dr. Stanley Nathanson, focusing on MHC gene variants and immune responses. Following this, he completed a post-doctoral fellowship (1982–1983) at Ben-Gurion University under Prof. Shraga Segal in microbiology and immunology. Later, from 1994 to 1997, he expanded into health policy and leadership by completing a Master’s in Health Management at Ben-Gurion University. His academic training encompasses a rich mix of molecular biology, immunogenetics, and clinical science, positioning him as a leader in translational cancer research and ethical practice in biomedical sciences.

Experience

Prof. Jacob Gopas has over four decades of academic and research experience. He began as a teaching assistant at Bar-Ilan and Yeshiva Universities and joined Ben-Gurion University in 1983 as a lecturer. He rose through the ranks, becoming a senior lecturer (1993), associate professor (2000), and full professor in 2014. From 1986 to 2022, he led the Oncology Laboratory at Soroka Medical Center, advancing cancer research and diagnostics. He held visiting scientist positions at the NIH and SUNY Health Science Center and was a fellow of the EORTC, EACR, and UICC. Prof. Gopas also led key university roles, such as Head of Recanati School for Community Health Professions, Head of Ethics Committees, and member of national ethics boards including the Israel Ministry of Health’s IACUC. His leadership has influenced both scientific innovation and ethical governance in Israeli biomedical research.

Awards and Honors

Prof. Jacob Gopas has been honored with multiple prestigious fellowships and appointments throughout his career. His notable awards include fellowships from the European Organization for Research and Treatment of Cancer (EORTC), the European Association for Cancer Research (EACR), and the International Union Against Cancer (UICC). These fellowships recognize his groundbreaking work in cancer biology and immunogenetics. His leadership in research ethics is equally commendable—he served as Head of the National Agency of Ethics in Animal Experimentation under the Israel Ministry of Health from 2016 to 2022, influencing policy at a national level. He was a member of the executive committee of the Israel Association for Cancer Research (IACR) (2021–2024) and represented the Israel National Academy of Sciences in ethical regulation. His achievements reflect a blend of scientific rigor, institutional leadership, and deep commitment to the responsible advancement of biomedical science.

Research Focus

Prof. Jacob Gopas’s research spans cancer biology, immunology, and translational medicine. His primary focus is the pathogenesis of Hodgkin’s lymphoma, particularly the molecular and immunological mechanisms behind its development and progression. He also investigates the development of natural compounds with anti-cancer, antimicrobial, and anti-inflammatory properties, aiming to identify effective, low-toxicity therapies. Another of his innovative projects explores the impact of obstructive sleep apnea on stem cell-derived human cardiomyocytes, linking sleep disorders with cardiovascular pathology. His interdisciplinary research integrates cell biology, molecular genetics, immunology, and pharmacology. Funded by agencies such as the NIH, Israel Ministry of Health, Israel Cancer Association, and Israel Science Foundation, his work has contributed to new therapeutic insights and ethical frameworks. Through collaborations, including with the Fox Chase Cancer Center, he continues to push boundaries in both laboratory science and clinical application, while mentoring emerging scientists in translational biomedical research.

Publication Top Notes

  1. Induction of B-lymphocyte colony growth in vitro by thymus derived stimulating factor.

  2. Lymphocyte colony growth in vitro.

  3. Mutants of the murine major histocompatibility complex: structural analysis of in vivo and in vitro H-2K variants.

  4. Analysis of somatic cell H-2 variants to define the structural requirements for class I expression.

  5. The immunobiology of metastatic processes: analysis of NK sensitivity and the metastatic potential of H-2 gene transfected fibrosarcoma cells.

  6. NK sensitivity, H-2, Ki-ras protooncogene expression and metastasis: Analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells.

  7. Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells.

  8. The relationship between MHC antigen expression and metastasis.

  9. Nephrotic syndrome associated with cell carcinoma of the bladder.

  10. The influence of murine and human major histocompatibility complex class I expression on tumor growth and metastasis.